INGELHEIM, Germany - Monday, September 2nd 2013 [ME NewsWire]

(BUSINESS WIRE)--For media outside the UK, US and Canada

    Results of COPD Phase III landmark trial TIOSPIR™ comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®
    Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD
    Phase III data from MezzoTinA-asthma® trials evaluating the efficacy and safety of tiotropium† Respimat® in asthma patients symptomatic on moderate-dose maintenance inhaled corticosteroid (ICS) therapy
    Results of LUX-Lung 6 Phase III trial demonstrating superiority of afatinib‡ over standard chemotherapy in lung cancer patients with EGFR mutations1,2

Results from TIOSPIR™ (Tiotropium Safety and Performance in Respimat), one of the largest global chronic obstructive pulmonary di ... Read more »